Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.58 |
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSD | P07339 | 3/20 | 0.56 |
| ▸ | REN | P00797 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11282264 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL11286012 | 0.94 | REN (0.57) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL11286016 | 0.94 | REN (0.57) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL28916808 | 0.91 | REN (0.63) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL30279290 | 0.91 | REN (0.63) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL10456411 | 0.91 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10944784 | 0.91 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL28916842 | 0.90 | CTSS (0.62) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL30279324 | 0.90 | CTSS (0.62) | CTSSCTSKCTSBCTSLCTSD | |
| SCHEMBL28961339 | 0.84 | CTSD (0.67) | CTSSCTSKCTSBCTSLCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382193-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-8921599-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20120107902-A1 | Processes For Forming Amide Bonds And Compositions Related Thereto | EMORY UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-4351828-A | N-Substituted cyclopeptide derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| US-4237045-A | N-substituted cyclopeptide derivatives and preparation thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315129-A1 | PROCESSES FOR FORMING AMIDE BONDS AND COMPOSITIONS RELATED THERETO | TMT1A, LPO, GSTO1 | CTSS 2126/4885CTSK 3357/4885CTSB 3818/4885 |
| US-20120107902-A1 | Processes For Forming Amide Bonds And Compositions Related Thereto | TMT1A, LPO, GSTO1 | CTSS 2126/4885CTSK 3357/4885CTSB 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.